Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Substrate Specificity and Biochemical Characteristics of an Engineered Mammalian Chondroitinase ABC

PM. Warren, JW. Fawcett, JCF. Kwok

. 2021 ; 6 (17) : 11223-11230. [pub] 20210419

Language English Country United States

Document type Journal Article

Chondroitin sulfate proteoglycans inhibit regeneration, neuroprotection, and plasticity following spinal cord injury. The development of a second-generation chondroitinase ABC enzyme, capable of being secreted from mammalian cells (mChABC), has facilitated the functional recovery of animals following severe spinal trauma. The genetically modified enzyme has been shown to efficiently break down the inhibitory extracellular matrix surrounding cells at the site of injury, while facilitating cellular integration and axonal growth. However, the activity profile of the enzyme in relation to the original bacterial chondroitinase (bChABC) has not been determined. Here, we characterize the activity profile of mChABC and compare it to bChABC, both enzymes having been maintained under physiologically relevant conditions for the duration of the experiment. We show that this genetically modified enzyme can be secreted reliably and robustly in high yields from a mammalian cell line. The modifications made to the cDNA of the enzyme have not altered the functional activity of mChABC compared to bChABC, ensuring that it has optimal activity on chondroitin sulfate-A, with an optimal pH at 8.0 and temperature at 37 °C. However, mChABC shows superior thermostability compared to bChABC, ensuring that the recombinant enzyme operates with enhanced activity over a variety of physiologically relevant substrates and temperatures compared to the widely used bacterial alternative without substantially altering its kinetic output. The determination that mChABC can function with greater robustness under physiological conditions than bChABC is an important step in the further development of this auspicious treatment strategy toward a clinical application.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21017940
003      
CZ-PrNML
005      
20210729104210.0
007      
ta
008      
210726s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acsomega.0c06262 $2 doi
035    __
$a (PubMed)34056277
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Warren, Philippa M $u Department of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge CB2 0PY, U.K $u Wolfson Centre for Age Related Diseases, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Guy's Campus, London Bridge, London SE1 1UL, U.K $u Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge CB2 0PY, U.K
245    10
$a Substrate Specificity and Biochemical Characteristics of an Engineered Mammalian Chondroitinase ABC / $c PM. Warren, JW. Fawcett, JCF. Kwok
520    9_
$a Chondroitin sulfate proteoglycans inhibit regeneration, neuroprotection, and plasticity following spinal cord injury. The development of a second-generation chondroitinase ABC enzyme, capable of being secreted from mammalian cells (mChABC), has facilitated the functional recovery of animals following severe spinal trauma. The genetically modified enzyme has been shown to efficiently break down the inhibitory extracellular matrix surrounding cells at the site of injury, while facilitating cellular integration and axonal growth. However, the activity profile of the enzyme in relation to the original bacterial chondroitinase (bChABC) has not been determined. Here, we characterize the activity profile of mChABC and compare it to bChABC, both enzymes having been maintained under physiologically relevant conditions for the duration of the experiment. We show that this genetically modified enzyme can be secreted reliably and robustly in high yields from a mammalian cell line. The modifications made to the cDNA of the enzyme have not altered the functional activity of mChABC compared to bChABC, ensuring that it has optimal activity on chondroitin sulfate-A, with an optimal pH at 8.0 and temperature at 37 °C. However, mChABC shows superior thermostability compared to bChABC, ensuring that the recombinant enzyme operates with enhanced activity over a variety of physiologically relevant substrates and temperatures compared to the widely used bacterial alternative without substantially altering its kinetic output. The determination that mChABC can function with greater robustness under physiological conditions than bChABC is an important step in the further development of this auspicious treatment strategy toward a clinical application.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Fawcett, James W $u Department of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge CB2 0PY, U.K $u Centre for Reconstructive Neuroscience, Institute of Experimental Medicine, Czech Academy of Sciences, Videnska 1083, 14220 Prague 4, Czech Republic
700    1_
$a Kwok, Jessica C F $u Department of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge CB2 0PY, U.K $u Centre for Reconstructive Neuroscience, Institute of Experimental Medicine, Czech Academy of Sciences, Videnska 1083, 14220 Prague 4, Czech Republic $u School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, U.K
773    0_
$w MED00207589 $t ACS omega $x 2470-1343 $g Roč. 6, č. 17 (2021), s. 11223-11230
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34056277 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210726 $b ABA008
991    __
$a 20210729104209 $b ABA008
999    __
$a ind $b bmc $g 1676472 $s 1138382
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 6 $c 17 $d 11223-11230 $e 20210419 $i 2470-1343 $m ACS omega $n ACS Omega $x MED00207589
LZP    __
$a Pubmed-20210726

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...